Prestige Consumer Healthcare completed its acquisition of LaCorium Health for approximately $150 million on July 1, 2026. The company also priced a $400 million offering of 6.25% senior notes due 2034, with proceeds intended to redeem $400 million of existing 5.125% senior notes due January 2028. LaCorium, an Australian therapeutic skincare company generating ~$40 million in annual revenue, is expected to contribute approximately $12 million in EBITDA post-integration.

While Alphabet's addition to the Dow and prominence in Berkshire Hathaway's portfolio has garnered significant attention, Prestige Consumer Healthcare may offer better investment potential. Prestige completed its largest acquisition, purchasing Breathe Right and other OTC brands for $1.045 billion, expanding its portfolio of category-leading brands. The company is also positioning itself to benefit from GLP-1 weight-loss medication side effects through its existing brands like Dramamine and Fleet. However, the acquisition has elevated debt to 4.0x EBITDA, requiring successful execution to reduce leverage by 2028.

Prestige Consumer Healthcare (PBH) shares dropped over 11% on May 14, 2026, after the company reported significant revenue declines and production problems at its recently acquired Pillar5 facility. The facility, which was supposed to resolve Clear Eyes supply chain constraints, failed to deliver expected results. Q4 2026 revenues fell 5% year-over-year, with North America OTC Eye & Ear Care declining 20.6%. Hagens Berman has opened an investigation into whether the company adequately disclosed these issues to investors.

Pomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. following the company's May 13, 2026 earnings announcement that revealed a 4.5% organic revenue decline and production issues with Clear Eyes products. The stock fell 11.35% to $45.93 per share on May 14, 2026, prompting the investigation into whether company officers and directors engaged in unlawful business practices.

The National Advertising Division reviewed advertising claims for eosera Inc.'s Ear Wax MD product in a challenge brought by Prestige Consumer Healthcare Inc. (marketer of Debrox). NAD found some establishment and mechanism-of-action claims were supported, but recommended discontinuing or modifying comparative superiority claims and unqualified effectiveness claims that overstated results. eosera agreed to comply with NAD's recommendations.

Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow. However, the stock shows technical weakness, trading below its moving averages with negative MACD signals.

Prestige Consumer Healthcare has agreed to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion ($900 million net of tax benefits). The acquisition includes the iconic #1 nasal strip brand and other established brands like Dimetapp® and Anbesol®. The deal is expected to close in fiscal 2027 and is projected to be immediately accretive to margins and EPS, with strong free cash flow generation supporting rapid deleveraging.

The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

Prestige Consumer Healthcare will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening, with a conference call at 8:30 a.m. ET to discuss results.

Prestige Consumer Healthcare will present at the Barclays Global Consumer Staples Conference, offering a live webcast of the event for investors and interested parties.

Prestige Consumer Healthcare Inc. announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on June 11, 2025. The company reported record fiscal 2025 revenue and earnings, with organic revenue growth of 7.9% in Q4 and 1.2% in fiscal 2025.

Prestige Consumer Healthcare reported strong Q4 and fiscal 2025 results, with record revenues, organic growth, and improved profitability. The company provided an initial outlook for fiscal 2026, anticipating continued growth and earnings expansion.